Outcomes of Radiotherapy and Chemotherapy in Elderly Patients 65 and Older with Advanced Head and Neck Squamous Cell Carcinoma

What this Trial Is About

Researchers are evaluating treatment outcomes in elderly patients aged 65 years and older with locally advanced head-and-neck squamous cell carcinomas HNSCC involving the oral cavity, oropharynx, hypopharynx, or larynx. The study aims to determine how definitive chemo-radiotherapy affects overall survival and progression-free survival in this vulnerable population, considering factors like age, performance status, and comorbidities. This retrospective multinational multicenter study addresses the limited evidence on optimal care for these patients. The study observes patients who have undergone definitive chemo-radiotherapy since 2005, focusing on modern radiotherapy techniques such as intensity-modulated radiotherapy IMRT and varying chemotherapy schedules, including weekly cisplatin. It assesses the impact of these treatments on survival outcomes and investigates the role of concomitant chemotherapy in this elderly cohort. Participants medical records are reviewed to collect data on overall survival up to five years and progression-free survival up to five years after treatment initiation. Researchers analyze patient characteristics, treatment details, and outcomes to understand the influence of therapy choices on survival. The study involves no new interventions or procedures, relying on existing clinical data from multiple centers.

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy